Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stada Expands Supply Network With Romanian Facility

Also Strikes German Deals With AOK And IKK For Cannabis Products

Executive Summary

Stada is investing nearly €50m in a Romanian supply-chain hub that it says will support future growth for the company, benefiting from its central European location. Meanwhile, the company has also struck medical cannabis deals with German insurers AOK and IKK.

You may also be interested in...



Dr Reddy’s Continues To Capitalize On German Cannabinoids With MediCane Launch

Dr Reddy's has announced that it will market MediCane’s medical cannabis portfolio across Germany, as part of a collaboration between the two companies which began last year.

Deal Watch: Amgen Taps Plexium's Expertise In Targeted Protein Degradation

Mersana will help J&J develop antibody-drug conjugates against three targets, while AstraZeneca out-licenses a candidate for peripheral artery disease to Regio.

Dr Reddy’s Steps Into 'Must-Be' Medical Cannabis Segment With German Deal

Dr Reddy’s enters high-potential medical cannabis fray with the acquisition of Nimbus Health in Germany. The segment has seen a flurry of activity over the recent past, including the $7.2bn acquisition of pioneer GW Pharmaceuticals.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151593

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel